Skip to main content

Drug Interactions between Alecensa and Zykadia

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

No interactions were found between Alecensa and Zykadia. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Alecensa

A total of 117 drugs are known to interact with Alecensa.

Zykadia

A total of 726 drugs are known to interact with Zykadia.

Drug and food interactions

Major

ceritinib food

Applies to: Zykadia (ceritinib)

Do not consume grapefruit or grapefruit juice during treatment with ceritinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of ceritinib to dangerous levels, increasing the risk of an irregular heart rhythm that may be serious. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, and hyperglycemia (high blood sugar) may also increase. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with ceritinib. Food may also increase the blood levels of ceritinib. Therefore, you should take ceritinib on an empty stomach, meaning no food should be eaten for at least two hours before or after taking ceritinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

alectinib food

Applies to: Alecensa (alectinib)

Food significantly increases the absorption of alectinib. You should take each dose of alectinib with food. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • Alecensa (alectinib)
  • Zykadia (ceritinib)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer